A Phase 2 interventional study of CM512 and Placebo in Perennial Allergic Rhinitis (PAR), sponsored by Beijing Keymed Biosciences Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Beijing Keymed Biosciences Co., Ltd. (part of Keymed Biosciences Co.Ltd) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a randomized, double-blind, placebo-parallel controlled phase II study to evaluate the safety and efficacy of CM512 in patients with perennial allergic rhinitis on background therapy
178 studies on the registry are indexed under Rhinitis, Allergic, Perennial; 9 are open to participants now.
This study's planned enrollment of 200 is above the median of 135 across 157 interventional studies indexed under Rhinitis, Allergic, Perennial.
Browse Rhinitis, Allergic, Perennial studies →Beijing Keymed Biosciences Co., Ltd. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: CM512
Drug: Placebo
Subcutaneous injection, multiple doses. Dosing every 12 weeks (Q12W) or Q24W, according to the protocol. Total treatment duration: 48 weeks.
Subcutaneous injection of matching placebo. multiple doses. Q12W or Q24W according to the protocol. Total treatment duration: 48 weeks.
Change from Baseline in Reflective Total Nasal Symptom Score (rTNSS) at Week 24
rTNSS was a composite of 4 symptoms (rhinorrhea, nasal congestion, nasal itching and sneezing), each symptom was scored on a scale of 0 = none, 1 = mild, 2 = moderate, 3 = severe. rTNSS is the sum of the rating of all 4 symptoms and ranges from 0-12.
Time frame: baseline, Week 24
Start is estimated for Oct 2026; primary completion for Jun 2028, 20 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CM512
Rhinitis, Allergic, Perennial →